Sign in
Not yet taking people in PolandPhase 1

RVU120 with everolimus in children whose medulloblastoma has returned or is growing

Tests RVU120 alone and with everolimus in children with recurring medulloblastoma.

Key facts

Who runs it
Instytut Pomnik Centrum Zdrowia Dziecka
Where
Warsaw, PolandSee the site
Registry title
Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY
Status
Not yet recruiting
Phase
Phase 1
People taking part
48 people, planned
Started
31 Jul 2026
Expected to end
30 Sept 2031
Type of study
Interventional
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teenagers whose Group 3 or Group 4 medulloblastoma has come back or is getting worse after first standard treatment.

Age
3 years to 18 years (the record also lists a maximum age of 17 years)
Sex
All sexes can join.
Disease stage
Group 3 or Group 4 medulloblastoma that has come back or is getting worse after first standard treatment. The group must be confirmed by a methylation test. Children with spread (metastatic) disease can join.
Earlier treatment
Must have recovered from the acute side effects (grade 1 or lower) of earlier chemotherapy, immunotherapy or radiotherapy. Must not have had a CDK8 inhibitor or an mTOR inhibitor such as everolimus, sirolimus or temsirolimus.
Biomarker or test result
Medulloblastoma group (Group 3 or Group 4) confirmed by CLIA-certified methylation testing, at diagnosis or at recurrence.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Serious unrelated illness that could make the treatment unsafe
  • Major surgery, including tumour biopsy, within 14 days before joining
  • Poor absorption of medicines from the gut, or major bowel or stomach surgery
  • Earlier treatment with a CDK8 inhibitor or an mTOR inhibitor

Where in Poland

  • Instytut Pomnik Centrum Zdrowia DzieckaWarsaw, PolandNot yet recruiting

About the trial

What the trial wants to find out

1. To evaluate the safety and toxicity of RVU120 as a single agent and combined with everolimus when administered to children with recurrent or progressive G3 or G4 medulloblastoma 2. To determine the MTD and/or RP2D of RVU120 as a single agent and in combination with everolimus in children with recurrent or progressive G3 or G4 medulloblastoma.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY
Plain-language title
RVU120 with everolimus in children whose medulloblastoma has returned or is growingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
28 October 2026